[ad_1] Suprachoroidal triamcinolone acetonide injectable suspension for macular edema associated with uveitis: Visual and anatomic outcomes by age | IOVS | ARVO Journals https://t.co/PJzKq2PW8X [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @ThomasCiullaMD: Congrats to colleagues & partners with numerous presentations involving #suprachoroidal delivery at last week’s #OIS &… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @ThomasCiullaMD: Recently published: https://t.co/5IyRrMAdlc “Sustained release glaucoma therapies: Novel modalities for overcoming key… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @BauschLomb: At the @asrsdocs annual meeting this week, five presentations will highlight data from the XIPERE® (triamcinolone acetonide… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @MarketScope_LLC: CMS Issues Permanent J-Codes for Xipere, Susvimo, Vyvgart: https://t.co/UWWkrGf2lJ [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Dr Steven Yeh on Patients Treated With Xipere and Its Use Over the Long Term https://t.co/nWhm7CUCJP via @AJMC_Journal [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @Ophthalmologymg: In his article, “Suprachoroidal Injections: Xipere and Beyond,” Mark R. Barakat, MD, discusses how targeting the supra… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.